Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:38 AM
Ignite Modification Date:
2025-12-25 @ 1:38 AM
NCT ID:
NCT05862194
Eligibility Criteria:
Inclusion Criteria:
* Target and Period: Patients aged 18 or older
* Target Conditions:
1. Lazertinib:
* Patients diagnosed with locally progressive or metastatic non-small cell lung cancer, who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
* Patients with T790M mutation positive
* Patients with an ECOG PS score of 0 to 1 at the time of initial drug administration
2. Platinum-based Chemotherapy
* Patients who were diagnosed with locally advanced or metastatic non-small cell lung cancer, and previously received first or second-generation EGFR-TKI treatment during the baseline period
* Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
* Patients who were confirmed positive for active EGFR mutations (L858R, Exon19Del, G719X, L861Q) during the baseline period
* Patients with an ECOG PS score of 0 to 1 at the time of initial drug administration
Exclusion Criteria:
* Patients with carcinoma besides NSCLC requiring treatment
* Any unstable brain metastasis with symptomatic and/or requiring emergency treatment
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05862194
Study Brief:
Protocol Section:
NCT05862194